SCHEMBL4439765

SCHEMBL4439765

NC(=O)c1ccc(-c2ccncc2)cc1OC(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 3/20 0.54
CSF1R P07333 1/20 0.51
CDC7 O00311 5/20 0.49
CDK9 P50750 1/20 0.49
MKNK2 Q9HBH9 8/20 0.48
MKNK1 Q9BUB5 7/20 0.48
ROCK2 O75116 3/20 0.46
MAP4K4 O95819 2/20 0.46
GSK3B P49841 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46
IKBKB O14920 2/20 0.45
PIM1 P11309 1/20 0.44
CDK2 P24941 1/20 0.44
EGFR P00533 2/20 0.44
FGFR1 P11362 2/20 0.44
KDR P35968 2/20 0.44
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
ROCK1 Q13464 1/20 0.41
IKBKE Q14164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448921 0.78 CHUK (0.58) CHUKCDC7CDK9MKNK2MKNK1
SCHEMBL31696469 0.77 TDP1 (0.46) CSF1RMKNK2MKNK1EGFRFGFR1
SCHEMBL4439767 0.77 AAK1 (0.49) CSF1RCDC7ROCK2MAP4K4GSK3B
Hydrochloric Acid SCHEMBL4439147 0.77 CHUK (0.56) CHUKCDC7CDK9MKNK2MKNK1
SCHEMBL3784025 0.75 ALDH1A1 (0.45)
SCHEMBL3784022 0.75 SLC6A2 (0.46)
SCHEMBL3778656 0.74 MAP2K1 (0.40)
SCHEMBL4441995 0.74 DGAT1 (0.54) KDR
SCHEMBL4638596 0.74 AVPR2 (0.47)
SCHEMBL20541755 0.74 SCN9A (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167348-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-07-10 US claimed
EP-2118062-A1 SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-11-18 EP disclosed
WO-2008084004-A1 SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-17 WO disclosed
US-20080167348-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167348-A1 NOVEL SULFONAMIDE DERIVATIVES CMA1, ARSA, TPSAB1 CHUK 345/4885CSF1R 1299/4885CDC7 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.